Utilizing CTCs in Solid Tumors
Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.
Leonard G. Gomella, MD, Chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the utilization of circulating tumor cells (CTCs) in patients with solid tumors.
A major challenge currently facing the use of CTCs is a lack of adequate assays to accurately detect low levels of cells. However, Gomella adds, techniques and gradient technologies are currently being assessed to alleviate sensitivity concerns with very low cell counts.
Clinical Pearls
An exciting area of research involves capturing CTC and interrogating them for genetic alterations, Gomella notes. In the future, this area of research will continue to be explored further.
- A major challenge currently facing the use of CTCs is a lack of adequate assays to accurately detect low levels of cells
- Techniques and gradient technologies are currently being assessed to alleviate sensitivity concerns with low cell counts
- Capturing and interrogating CTCs for genetic alterations is currently an exciting area of research
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
